# Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome

> **NCT00673816** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Eye Institute (NEI)** · enrollment: 2 (actual)

## Conditions studied

- Von Hippel-Lindau Syndrome

## Interventions

- **DRUG:** Sunitinib Malate

## Key facts

- **NCT ID:** NCT00673816
- **Lead sponsor:** National Eye Institute (NEI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Inability to recruit and adequate number of participants
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673816, "Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00673816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*